Express News | Autolus Therapeutics to Present Key Data on AUCATZYL At 2025 Tandem Meetings, Highlighting Cost Benefits and Clinical Outcomes
Autolus Therapeutics to Present Data at 2025 Tandem Meetings on AUCATZYL and Its Economic Impact Compared to CAR-T Therapies
Wells Fargo Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $8
Positive Buy Rating for Autolus Therapeutics Driven by Aucatzyl's Promising Launch and Strategic Growth Prospects
Autolus Reports FDA Approval and NCCN Inclusion of AUCATZYL, Sets Milestones for Pipeline Growth
Press Release: Autolus Therapeutics Provides Business Updates and 2025 Overview
blessings u : Thank you for sharing.
Trytosaveabit OP blessings u : you’re welcome![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")